title: Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study.
abstract: OBJECTIVE
  To compare etanercept (anti-tumor necrosis factor-α) with intraarticular (IA) corticosteroid injections to treat rheumatoid arthritis (RA).
  
  
  METHODS
  Patients with RA who had persistent monoarthritis received etanercept or IA corticosteroid injections. Efficacy was compared at Weeks 4 and 24.
  
  
  RESULTS
  Thirty-four patients were included (8 dropped out). Mean age was 58.8 years. No difference between groups was found at Weeks 4 or 24, but both groups showed significant improvement at Weeks 4 and 24 compared to baseline.
  
  
  CONCLUSIONS
  Etanercept and IA steroid injections resulted in significant improvement at Week 4 that persisted to Week 24. There was no significant difference in outcome between the groups.
authors.affiliation: Rheumatology Department, Hospital l'Archet 1, 242 Route de Saint Antoine de Ginestiere, 06200 Nice, France. roux101fr@yahoo.fr
authors.forename: Christian H
authors.initials: CH
authors.lastname: Roux
authors.forename: Veronique
authors.initials: V
authors.lastname: Breuil
authors.forename: Laure
authors.initials: L
authors.lastname: Valerio
authors.forename: Nicolas
authors.initials: N
authors.lastname: Amoretti
authors.forename: Olivier
authors.initials: O
authors.lastname: Brocq
authors.forename: Christine
authors.initials: C
authors.lastname: Albert
authors.forename: Christian
authors.initials: C
authors.lastname: Grisot
authors.forename: Yacine
authors.initials: Y
authors.lastname: Allam
authors.forename: Patrick
authors.initials: P
authors.lastname: Chevalier
authors.forename: Christian
authors.initials: C
authors.lastname: Pradier
authors.forename: Lianna
authors.initials: L
authors.lastname: Euller-Ziegler
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001799:Blood Sedimentation; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007270:Injections, Intra-Articular; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014463:Ultrasonography
chemical_list: D000305:Adrenal Cortex Hormones; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept